用于纵向癌症患者监测的数字熔解曲线分析平台-猫眼课题宝

用于纵向癌症患者监测的数字熔解曲线分析平台

批准号：

10256226

负责人：

Paul Ju-Sung Hung

金额：

$77.27万

依托单位：

COMBINATI, INC.

依托单位国家：

美国

项目类别：

财政年份：

2021

资助国家：

美国

项目状态：

已结题

起止时间：

2021-04-01 至 2021-05-11

来源：

https://reporter.nih.gov/project-details/10256226

关键词：

Adopted Adoption Architecture Back Biological Assay Blinded Breast Cancer Patient Calibration Cancer Patient Chemistry Clinical Collection Color Computer software Computers DNA Dana-Farber Cancer Institute Data Data Analyses Development Dimensions ESR1 gene Evolution Gene Frequency Genomics Genotype Goals Gold Image Image Analysis Journals Letters Light Mainstreaming Manuscripts Mechanics Memory Metastatic breast cancer Microfluidics Monitor Mutation Nucleic Acids Optics Oranges Patient Monitoring Patients Peer Review Performance Phase Process Protocols documentation Publications Reagent Reproducibility Research Resolution Risk Running Sampling Science Small Business Innovation Research Grant Source Speed System Technology Temperature Testing Time Training Validation cell free DNA clinically relevant cost cyanine dye 5 data exchange design detection limit digital fluorescence imaging graphical user interface image processing improved instrument invention lens liquid biopsy machine learning algorithm meetings melting multidimensional data mutant mutation assay neural network product development sensor simulation

项目摘要

项目成果

Paul Ju-Sung Hung的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

Abstract Building on its commercially available Absolute Q digital PCR platform, during the 24-month Phase 2 SBIR project, Combinati will complete the development of the first Digital Melt Curve Analysis (DMCA) platform to the market to further advance the adoption of digital genomics for highly accurate, sensitive and reproducible nucleic acid quantification for longitudinal patient monitoring. To provide the “whole product” solution and prove the function, we will demonstrate the DMCA platform with Luminex’s 11- plex ESR1 (Estrogen Receptor 1) assay and conduct Beta testing at Dana Farber Cancer Institute: 1. Three beta instruments and the analysis software capable of digital melt curve analysis. 2. Complete dMCA validation internally with commercially available melt calibration kits. 3. Demonstrate <0.1% Mutation Allele Frequency of 11 cell-free DNA targets using Luminex Corporation’s discrete melt assay. 4. Beta testing at Dana Farber Cancer Institute

期刊论文(0)

专著(0)

科研奖励(0)

会议论文